Condition: Clostridium Difficile · Clostridium Difficile Infections · Clostridium Difficile Infection Recurrence · Sponsor: Vedanta Biosciences, Inc.
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).
This description comes directly from the study's public registry record.
Gary Connor · 857-706-1427 · Consortium02-ctinquiries@vedantabio.com
Steven Shiff, MD · 857-706-1427 · Consortium02-ctinquiries@vedantabio.com
Always discuss trial participation with your own doctor first.
| Metro Infectious Disease Consultants | Huntsville, Alabama, United States | Recruiting |
| Advanced Gastroenterology, P.C. | Chandler, Arizona, United States | Withdrawn |
| Mayo Clinic Hospital | Phoenix, Arizona, United States | Withdrawn |
| GI Alliance | Sun City, Arizona, United States | Recruiting |
| Om Research, LLC | Apple Valley, California, United States | Withdrawn |
| Science 37 Inc (Remote/Home option) | Culver City, California, United States | Recruiting |
| Children's Hospital of Los Angeles | Los Angeles, California, United States | Recruiting |
| VA San Diego Healthcare System | San Diego, California, United States | Recruiting |
| North America Research Institute | San Dimas, California, United States | Withdrawn |
| Clinical Trials Management Services | Thousand Oaks, California, United States | Recruiting |
| Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Torrance, California, United States | Recruiting |
| Connecticut Clinical Research Institute | Bristol, Connecticut, United States | Recruiting |
+ 203 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06237452